Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.
Twist Bioscience Corporation (TWST) is a leader in synthetic DNA production, utilizing a proprietary semiconductor-based platform to drive innovations across biotechnology and healthcare. This page provides investors and industry professionals with timely, accurate updates on TWST's strategic developments and operational milestones.
Access consolidated press releases and news covering earnings announcements, product launches, research breakthroughs, and partnerships. Our curated updates ensure you stay informed about TWST's advancements in gene synthesis, high-throughput manufacturing, and applications in precision medicine.
Key content includes quarterly financial results, regulatory filings, technology patents, and collaborations with academic or industry partners. All materials are sourced directly from verified company communications to maintain factual integrity.
Bookmark this page for streamlined access to TWST's evolving role in synthetic biology. Check regularly for critical updates impacting market positioning and technological leadership in DNA synthesis.
Twist Bioscience (TWST) and Centogene (CNTG) have launched three next-generation sequencing target enrichment panels aimed at advancing research and diagnostics for rare diseases and hereditary cancers. These panels enhance the precision of genetic sequencing and are based on data from Centogene's Biodatabank, which includes nearly 700,000 patients. The products include the Twist Alliance CNTG Exome Panel, CNTG Rare Disease Panel, and CNTG Hereditary Oncology Panel. This collaboration is expected to improve diagnostic capabilities worldwide, facilitating earlier disease detection and treatment development.
Twist Bioscience (NASDAQ: TWST) has announced a research collaboration with Astellas Pharma Inc to discover antibodies targeting diseases with high unmet medical needs. This partnership, following a successful initial collaboration, highlights Twist's antibody discovery capabilities through its Library of Libraries. Under the agreement, Twist will receive an upfront payment, project-specific research fees, and earn up to
Twist Bioscience Corporation (NASDAQ: TWST) announced that CEO and co-founder Emily M. Leproust, Ph.D., will present at the 41st Annual J.P. Morgan Health Care Conference on January 9th at 5:15 p.m. PST. The live presentation will be webcast and accessible via the company's investor relations page. A replay will be available for 30 days post-event. Twist Bioscience specializes in synthetic DNA production using its proprietary silicon platform to create products for various sectors including healthcare and agriculture.
Twist Bioscience Corporation (NASDAQ: TWST) will host investors at its Factory of the Future on
Twist Bioscience reported record revenue of $203.6 million for Fiscal 2022, marking a 54% increase from the previous year. Orders rose to $226 million, up 42% year-over-year. The company forecasts revenue between $261 million and $269 million for Fiscal 2023 and anticipates $350 million in Fiscal 2024. Despite growth, net loss for Fiscal 2022 widened to $217.9 million, or $4.04 per share. The company aims to enhance its position in next-generation sequencing (NGS) and introduce new products in 2023, including a DNA data storage solution.
Twist Bioscience Corporation (NASDAQ: TWST) plans to release its fiscal Q4 and full year 2022 financial results on
Twist Bioscience Corporation (NASDAQ: TWST) will release its financial results for the fiscal 2022 fourth quarter and full year on November 18, 2022, before market opening. A conference call and audio webcast will be held at 8:00 a.m. Eastern Time to discuss the results and provide a business update. Twist specializes in synthetic DNA synthesis using its innovative silicon platform, producing products for various sectors like healthcare and agriculture. The financial results will be available on the company's website prior to the call.
Twist Bioscience Corporation (NASDAQ: TWST) and Illumina, Inc. (NASDAQ: ILMN) announced a partnership to enhance research capabilities with the co-branded Twist® for Illumina® Exome 2.0 Plus panel. Twist will manufacture the panel, which features high uniformity, low off-target rates, and is designed for Illumina sequencers. This collaboration aims to provide a market-leading exome panel, facilitating improved customer access to advanced genomic solutions. Both companies are recognized as leaders in genomics and next-generation sequencing.
Twist Bioscience Corporation (NASDAQ: TWST) has announced the promotion of Patrick Finn, Ph.D., to the role of president and chief operating officer. Dr. Finn, who previously served as chief commercial officer, has significantly contributed to the company's growth, increasing sales from $2 million in fiscal 2016 to $184 million for the 12 months ending June 30, 2022. His promotion is part of Twist's strategy to expand its global presence and enhance operational capabilities, aiming for increased market share in synthetic biology, NGS, and biopharma.
Twist Bioscience Corporation (NASDAQ: TWST) has launched the Twist Human Sample ID Kit, designed to track samples in next-generation sequencing (NGS) workflows. This innovation aims to minimize sample mix-ups, reducing the necessity for test re-runs and enhancing data accuracy. It is compatible with Twist NGS workflows, allowing quick identification of samples from whole blood. The kit will be showcased at the American Society of Human Genetics Annual Meeting on October 26, 2022, highlighting its capability of improving precision in genetic research.
FAQ
What is the current stock price of Twist Bioscience (TWST)?
What is the market cap of Twist Bioscience (TWST)?
